Ellington Management Group’s Atara Biotherapeutics ATRA Stock Holding History

Ellington Management Group’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-980	Closed	-$208K	–	68
2020 Q1	$208K	Buy	+980	New	+$311K	0.05%	428
2018 Q2	–	Sell	-1,664	Closed	-$1.62M	–	512
2018 Q1	$1.62M	Buy	+1,664	New	+$1.52M	0.12%	96
2017 Q2	–	Sell	-428	Closed	-$220K	–	641
2017 Q1	$220K	Buy	+428	New	+$177K	0.01%	553

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ellington Management Group's ATRA Position: Q2 2020 in Review

Ellington Management Group sold out of Atara Biotherapeutics (ATRA) in Q2 2020, closing a stake of 980 shares — an estimated $208K sold.

Ellington Management Group first reported a position in ATRA in Q1 2017 and held it in 3 quarters. The position peaked at $1.62M in Q1 2018. 122 funds tracked by Wall St. Rank hold ATRA as of Q2 2020.

Ellington Management Group reported no remaining Atara Biotherapeutics position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 980 Atara Biotherapeutics shares in Q2 2020, an estimated $208K.
Ellington Management Group first reported a position in Atara Biotherapeutics in Q1 2017 and held it in 3 quarters.
Ellington Management Group's Atara Biotherapeutics position peaked at $1.62M in Q1 2018.
122 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.